#H2 Receptor Antagonist Research Report

[credenceresearchdotblog]

The Gastrointestinal Agents Market is projected to grow from USD 59,863.47 million in 2023 to USD 92,867.89 million by 2032, reflecting a compound annual growth rate (CAGR) of 5.00%.The gastrointestinal (GI) agents market is a rapidly growing sector within the global pharmaceutical industry, driven by the increasing prevalence of gastrointestinal disorders, advancements in drug development, and rising awareness about digestive health. This article explores the key trends, market drivers, challenges, and future outlook of the gastrointestinal agents market.

Browse the full report at https://www.credenceresearch.com/report/gastrointestinal-agents-market

Overview of the Gastrointestinal Agents Market

Gastrointestinal agents are medications used to treat disorders of the digestive system, including conditions like gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), peptic ulcers, Crohn's disease, and ulcerative colitis. These agents are categorized into several classes, such as antacids, proton pump inhibitors (PPIs), H2 receptor antagonists, laxatives, antidiarrheals, and antiemetics. The global gastrointestinal agents market has witnessed significant growth due to the rising incidence of these disorders, coupled with lifestyle changes, aging populations, and increasing adoption of unhealthy diets.

Key Market Drivers

1. Rising Prevalence of Gastrointestinal Disorders: The increasing incidence of GI disorders is a major driver of the market. According to the World Gastroenterology Organization, gastrointestinal diseases affect millions of people worldwide, with a particularly high prevalence in developed countries due to sedentary lifestyles, poor diet, and high levels of stress.

2. Aging Population: The growing aging population is another critical factor contributing to market growth. Older adults are more susceptible to gastrointestinal issues due to age-related changes in the digestive system, making them a key demographic for GI agents.

3. Advancements in Drug Development: Ongoing research and development activities have led to the introduction of novel GI agents that offer improved efficacy and safety profiles. Biologics and targeted therapies, for example, are gaining traction in the treatment of inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis.

4. Increased Awareness and Diagnosis: Enhanced awareness about digestive health and the availability of advanced diagnostic tools have resulted in the early detection and treatment of GI disorders, further boosting the demand for gastrointestinal agents.

5. Rising Healthcare Expenditure: Increased healthcare spending, particularly in emerging economies, has improved access to healthcare services and medications, propelling the growth of the GI agents market.

Challenges Facing the Market

1. Side Effects and Safety Concerns: Many gastrointestinal agents, especially long-term treatments such as PPIs, have been associated with side effects like kidney issues, infections, and bone fractures. Safety concerns can lead to regulatory restrictions and affect market growth.

2. High Cost of Advanced Therapies: The cost of new biologics and targeted therapies can be prohibitive for patients and healthcare systems, particularly in low- and middle-income countries. This cost barrier may limit market expansion in some regions.

3. Generic Competition: The expiration of patents for several blockbuster drugs has led to the entry of generic versions, which, while increasing accessibility, have also intensified competition and put pressure on market prices.

Future Outlook and Opportunities

The gastrointestinal agents market is poised for continued growth, with several opportunities on the horizon:

1. Innovation in Drug Delivery Systems: Innovations in drug delivery systems, such as delayed-release formulations, are expected to enhance the effectiveness of GI agents and improve patient compliance.

2. Personalized Medicine: The development of personalized medicine approaches, where treatment is tailored based on genetic and environmental factors, is gaining momentum. This approach promises to optimize treatment outcomes for GI disorders, particularly IBD.

3. Expansion in Emerging Markets: Emerging markets, including Asia-Pacific and Latin America, offer significant growth opportunities due to improving healthcare infrastructure, increasing disposable incomes, and growing awareness about GI disorders.

4. Digital Health and Remote Monitoring: The integration of digital health technologies and remote monitoring solutions is expected to improve the management of chronic GI conditions, enabling better patient outcomes and driving the demand for GI agents.

Key Player Analysis

Johnson & Johnson

Pfizer Inc.

AstraZeneca

AbbVie Inc.

Takeda Pharmaceuticals

Bayer AG

GlaxoSmithKline plc.

Sanofi

Allergan

Boehringer Ingelheim

Segments:

Based on Type:

Dietary Supplements

Drugs

Antacids

Anti-diarrheal Agents

Anti-emetics

H2 Blockers

Laxatives

Proton Pump Inhibitors

Based on Disease Type:

Constipation

Diarrhoea

Gastroesophageal Reflux Disease

Inflammatory Bowel Disease

Peptic Ulcer Disease

Based on Route of Administration:

Oral

Parenteral

Rectal

Based on End-User:

Homecare

Hospitals & Clinics

Based on Distribution Channel:

Offline Pharmacies

Online Pharmacies

 Based on the Geography:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/gastrointestinal-agents-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[businessmarketreports]

An Overview of the Reflux Esophagitis Pipeline Drugs Market

Gastroesophageal reflux disease (GERD), a chronic condition characterized by the upward flow of stomach acid into the esophagus, affects millions worldwide. The search for effective and safe treatments has fueled a robust pipeline of drugs targeting reflux esophagitis.

Buy the Full Report for More MoA Insights into the Gastroesophageal Reflux Disease Marketed Drugs, Download a Free Report Sample

Key Therapeutic Areas in the Pipeline

The pipeline for reflux esophagitis drugs focuses primarily on addressing the underlying causes of the disease, such as impaired lower esophageal sphincter (LES) function and increased acid production.

Proton Pump Inhibitors (PPIs): While PPIs are currently the mainstay of treatment, research is ongoing to develop novel PPIs with improved efficacy and safety profiles.

H2 Receptor Antagonists: Although second-line agents, there's continued interest in developing more potent and long-acting H2 blockers.

Gastric Motility Agents: Drugs targeting gastric motility disorders, which contribute to GERD, are under investigation.

Local Esophageal Therapies: Development of drugs with local action on the esophageal mucosa to heal inflammation and protect against acid damage.

Neuromodulators: Targeting neurotransmitters involved in esophageal function to address GERD symptoms.

Key Players and Their Pipeline

Several pharmaceutical companies are actively involved in the development of new treatments for reflux esophagitis. While established players like AstraZeneca, Pfizer, and Takeda have a strong presence, there's also a growing number of biotech companies focusing on this therapeutic area.

AstraZeneca: The company has a pipeline of drugs targeting different aspects of GERD, including acid suppression and mucosal protection.

Pfizer: With a strong portfolio of gastrointestinal drugs, Pfizer continues to invest in research and development for GERD.

Takeda: The acquisition of Shire has expanded Takeda's presence in the gastrointestinal disease area, including GERD.

Challenges and Opportunities

The development of new drugs for reflux esophagitis is a complex process. Key challenges include:

High Development Costs: The cost of clinical trials and regulatory hurdles can be substantial.

Competitive Landscape: The market is already crowded with existing treatment options, making it challenging for new drugs to gain market share.

Patient Heterogeneity: The diverse nature of GERD symptoms and patient populations makes it difficult to develop a one-size-fits-all treatment.

Despite these challenges, the pipeline for reflux esophagitis drugs holds significant promise. The potential to develop more effective and well-tolerated treatments could significantly improve the lives of millions of patients suffering from this condition.

[chetanare]

Global H2 Receptor Antagonist Market Size, Share, Development, Growth And Demand Forecast To 2026

Global H2 Receptor Antagonist Market Size, Share, Development, Growth And Demand Forecast To 2026

“Global H2 Receptor Antagonist Sales Market (Sales, Revenue and competitors Analysis of Major Market) from 2014-2026” the new research report adds in kandjmarketresearch.com research reports database. This Research Report spread across 105 Pages, with summarizing Top companies and supports with tables and figures.

A fresh specialized intelligence report published by KandJ Market Research with…

[palesoultaco]

GERD Drugs and Devices Market Demand Analysis, Statistics, Industry Growth Research Report till 2027

The Global GERD Drugs and Devices market Report offers extensive knowledge and information about the GERD Drugs and Devices market pertaining to market size, market share, growth influencing factors, opportunities, and current and emerging trends. The report is formulated with the updated and latest information of the GERD Drugs and Devices market further validated and verified by the industry experts and professionals. The report additionally sheds light on the emerging growth opportunities in the business sphere that are anticipated to bolster the growth of the market.

Gastroesophageal Reflux Disease is growing due to the intake of analgesics, smoking, decrease in the prevalence of Helicobacter pylori infection, consumption of certain types of food and drinks, high body mass index (BMI), family history of GERD, and limited physical activity. The growing incidence of the disease will drive the demand for the GERD drug and devices market.

The factors impacting the growth of the market are the rise in the trend of self-medication and increased awareness of GERD. Moreover, the constant occurrence of GERD disorders, as well as changes in lifestyle, are propelling the market demand. The expiration of the patent on most of the drugs is paving the way for new over the counter and generic drugs. The poor reimbursement of procedures and devices, low safety, and efficacy are restricting the adoption of the GERD drugs and devices market.

Click the link to get info@ https://www.emergenresearch.com/industry-report/gerd-drugs-and-devices-market

Some Key Highlights of Report

In November 2020, Sandoz Inc. announced it had shipped pantoprazole sodium to supply the hospitals for injection, 40 mg to Civica Rx. It is a part of a multiyear collaboration for the reduction in supply shortages with several other pipeline medicines.

H2 blockers are a group of drugs that reduces the amount of acid produced by the cell lining of the stomach. They are also known as histamine H2-receptor antagonists but are also known as H2 blockers. They include ranitidine, cimetidine, nizatidine, and famotidine, among others.

The MUSE or Medigus Ultrasonic Surgical Endostapler is an extensive endoscopic device that incorporates the latest technological advancement for the delivery of patient-friendly option for Transoral Fundoplication, the procedure intended for the treatment of GERD.

Overview of the TOC of the Report:

Introduction, Scope, and Overview

Opportunities, Risks, and Drivers

Competition landscape analysis with sales, revenue, and price

Extensive Profiling of the key competitors with the sales figures, revenue, and market share

Regional analysis with sales, revenue, and market share for each region for the forecast period

Country-wise analysis of the GERD Drugs and Devices market by type, application, and manufacturers

GERD Drugs and Devices Market Segmentation based on types

GERD Drugs and Devices Market segmentation based on applications

Historical and forecast estimation

Competitive Landscape:

Furthermore, the report includes an in-depth analysis of the competitive landscape. The segment covers a comprehensive overview of the company profiles along with product profiles, production capacities, products/services, pricing analysis, profit margins, and manufacturing process developments. The report also covers strategic business measures undertaken by the companies to gain substantial market share. The report provides insightful information about recent mergers and acquisitions, product launches, collaborations, joint ventures, partnerships, agreements, and government deals.

Key participants include Johnson & Johnson, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis AG, GlaxoSmithKline Plc, Merck & CO., Inc., Boston Scientific Corporation, Eisai Co., Ltd., and Ironwood Pharmaceuticals, Inc., among others.

For the purpose of this report, Emergen Research has segmented into the global GERD Drugs and Devices Market on the basis of route of administration, drug type, device type, and region:

Route Of Administration Outlook (Revenue, USD Billion; 2017-2027)

Oral

Parenteral

Drug Type Outlook (Revenue, USD Billion; 2017-2027)

H2 Receptor Antagonist

Proton Pump Inhibitor (PPIs)

Antacids

Device Type Outlook (Revenue, USD Billion; 2017-2027)

MUSE –Medigus Ultrasonic Surgical Endostapler

LINX Management System

Stretta Therapy

Bravo Reflux Testing System

Digitrapper reflux testing system

Others

Key takeaways of the Global GERD Drugs and Devices Market report:

The report sheds light on the fundamental GERD Drugs and Devices market drivers, restraints, opportunities, threats, and challenges.

It elaborates on the new, promising arenas in the leading GERD Drugs and Devices market regions.

It examines the latest research & development projects and technological innovations taking place in the key regional segments.

The research report reviews the regulatory framework for creating new opportunities in various regions of the GERD Drugs and Devices market

It focuses on the new revenue streams for the players in the emerging markets.

Furthermore, the report offers vital details about the rising revenue shares and the sizes of the key product segments.

Thank you for reading our report. Customization of the report is available. To know more, please connect with us, and our team will ensure the report is customized as per your requirements.

Take a Look at our Related Reports:

healthcare it market

https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/healthcare-it-market

coal tar market

https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/coal-tar-market

ir spectroscopy market

https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/ir-spectroscopy-market

eubiotics market

https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/eubiotics-market

nanotechnology market

https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/nanotechnology-market

ed-tech and smart classroom market

https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/ed-tech-and-smart-classroom-market

digital payment market

https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/digital-payment-market

signal conditioning modules market

https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/signal-conditioning-modules-market

About Us:

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

[reportsandreports]

Global H2 Receptor Antagonist Sales Market Report

ReportsnReports added Global H2 Receptor Antagonist Sales Market Research Report created by Report Consultant, which offers detailed insights, revenue details, and other information regarding the global market, and the various trends, drivers, restraints, opportunities, and market till 2028. Global H2 Receptor Antagonist Sales Market Report offers detailed information regarding the leading key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions and mergers, and market footprint. Global H2 Receptor Antagonist Sales Market also provides a comparative analysis of the market dynamics pre and post Covid19 outbreak.

Request for FREE PDF Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4436594

[snehalaxel]

Global GERD Market Will Generate New Growth Opportunities by 2027

"

GERD Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

Sample Copy of This Report:https://axelreports.com/request-sample/64453

A 360 degree outline of the competitive scenario of the Global GERD Market is presented by Axel Reports Market Insights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the market’s future growth, wide-ranging analysis of these extensions on the market’s future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Reasons for buying this report:

It offers an analysis of changing competitive scenario.

For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies.

It offers seven-year assessment of Global GERD

It helps in understanding the major key product segments.

Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.

It offers regional analysis of Global GERD Market along with business profiles of several stakeholders.

It offers massive data about trending factors that will influence the progress of the Global GERD

Get ToC for the overview of the premium report @ https://axelreports.com/industry-analysis/2021-2027-global-and-regional-gerd-indus/64453

By Market Players: AstraZeneca Johnson & Johnson Eisai GlaxoSmithKline Takeda By Type Proton Pumps Inhibitors H2 Receptor Antagonists Antacids Prokinetics CAM By Application Hospital Pharmacy Drug Stores General Stores Supermarkets

A detailed outline of the Global GERD Market includes a comprehensive analysis of different verticals of businesses. North America, Latin America, Asia-Pacific, Africa, and Europe have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global GERD Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global GERD Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global GERD Market. The feasibility of the new report is also measured in this research report.

Make an Enquiry for purchasing this Report :https://axelreports.com/enquiry-before-buying/64453

Table of Contents:

Global GERD Market Overview

Economic Impact on Industry

Market Competition by Manufacturers

Production, Revenue (Value) by Region

Production, Revenue (Value), Price Trend by Type

Market Analysis by Application

Cost Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Global GERD Market Forecast

ABOUT US:

Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact: Axel Reports Akansha G (Knowledge Partner) Office No- B 201 Pune, Maharashtra 411060 Phone: US +18488639402 Email: sales@axelreports.com/ Web: https://axelreports.com/

"

[siglerprescriptiondrugcards]

Ginger

Scientific Names: Zingiber officinale (syn. Amomum zingiber) Other Common Names: Imber, shoga, jiang Overall Safety: 🙂

Therapeutic Efficacy and Considerations:

Motion Sickness: 😊 Evidence evaluating ginger for prophylaxis and treatment of motion sickness is somewhat contradictory, but the largest trials did note benefit greater than placebo and similar to OTC remedies. Furthermore, ginger demonstrated no significant side effects versus placebo while centrally acting medications demonstrated drowsiness, dizziness, tinnitus, dry mouth, blurred vision, nervousness, and insomnia. Dose: 500-1000 mg of dried, powdered whole root up to two hours before stimulus, followed by 500 mg more every 4 hours thereafter. For extracts, the Zintona brand was shown to be effective in the trials with positive results.

Postoperative Nausea and Vomiting: 😐 Evidence for use in postoperative nausea and vomiting (PONV) is conflicting. Five studies and one meta-analysis have found non benefit. At this time, while the evidence does not support a general recommendation for use of ginger for PONV for all patients, there is sufficient evidence for ginger to be considered a valid option for individual patients who are not candidates for standard antiemetic agents or who are insistent upon a “natural remedy.” Dose: 1-1.5 grams of dried, powdered root prior to surgery.

Nausea/Vomiting of Pregnancy: 😊 Eight controlled trials, the four largest of high quality, have demonstrated that ginger is effective for relieving nausea and vomiting of pregnancy. A recent systemic review of the trials concluded that ginger could be an effective treatment. A survey of women who took ginger in their first trimester and the safety data from follow-up in the efficacy studies found no difference in malformations or adverse pregnancy outcomes between women who took ginger and normal incidences. Larger studies are needed for definite knowledge, but current evidence does support use. Dose: 250 mg four times daily. Use of large doses (especially >4 grams) should be avoided.

Osteoarthritis: 😐 Three studies have examined ginger’s effects in the treatment of osteoarthritis with mixed results. More research is warranted, but the current evidence is insufficient to make a general recommendation for use. Ginger may be an acceptable option in some individual patients, but treatments with a greater amount of evidence for efficacy, such as glucosamine sulfate, should be tried first. Dose: not established. Avoid more than 4 g daily and take in 2-4 divided doses.

Chemistry/Pharmacology: Two components, 6-shogaol and galanolactone, are responsible for antiemetic properties of ginger and act directly on the serotonin receptor 5-HT3 in the GI tract, but not in the CNS. Ginger does not seem to increase GI motility, but it may act directly on the gut to relax the cardiac sphincter and prevent movement of gastric contents upward. The constituents 6-gingerol and 6-shogaol have anti-inflammatory actions via inhibition of cyclooxygenase and lipoxygenase pathways. Antiplatelet activity is due to the inhibition of platelet thromboxane formation and prostaglandin inhibition provides antipyretic action. Ginger increases amylase and salivary production, which may be associated with improved digestive function. Two components, gingerol and zingerone, provide antioxidant activity by inhibition of lipoxygenase and elimination of radical superoxide.

Drug Interactions: May cause a serious risk of bleeding when used with anticoagulant and antiplatelet agents. May cause hypoglycemia potentiated by hypoglycemic drugs. Theoretically, ginger may increase production of stomach acid causing antacids, H2-antagonists, and proton pump inhibitors to be less effective.

Contraindications/Precautions: Doses >1 g/day are contraindicated in pregnancy due to lack of safety information at higher doses. Like most dietary supplements, ginger should be stopped 7-14 days prior to surgery. Avoid in patients with gallstones without full medical evaluation. One case report suggests that use in patients with bowel disease or obstruction be avoided. Use cautiously in patients with ulcers due to possible esophageal or gastric irritation; use of encapsulated ginger products may minimize irritation.

Adverse Effects: Generally, very well tolerated with mild heartburn as the most common side effect. Other effects reported are abdominal discomfort, diarrhea, nausea, mouth and throat irritation. Applied topically, some patients experience contact dermatitis with regular, repeated use.

[millioninsights]

Gastroesophageal Reflux Disease (GERD) therapeutics market is estimated to be USD 4.34 billion by 2025

Industry Insights

The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and by is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market.

With strong clinical pipelines and patent litigations, the market continues to experience significant changes. Proton pump inhibitors (PPI) and antagonists of histamine H2 receptor have the importance in current scenario of the market.

Upon loss of patent protection of formerly leading branded drugs, generic molecules with low-price can ingest the sales of the branded ones up to 90%. Rising number of companies being exposed to price scrutiny associated with shift in the focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices. Although market turnover is affected by the expiration of major patents and the demand of drugs used to reduce acid, due to the increasing prevalence of heartburn, is anticipated to increase in the upcoming years.

The devices of GERD serves as a substitute for management of heartburn, because of low rate of success and failure in clinical trials. Hence, very limited acceptance of devices of GERD management contribute for the rising demand of drugs having acid neutralizing property, as the major therapy approach.

Nevertheless, the advent of devices which are minimally invasive to address anatomical defects are gaining popularity coupled with supportive evidence from clinical data for performing various procedures including trans oral fundoplication, which helps in preventing reflux of non-acid and acid contents. The adoption of these devices have been further reinforced in the U.S. in 2016 with the advent of a CPT code (43210) which helps in facilitating reimbursement process.

Drug Type Insights

In 2016, market was dominated by the antacids segment and is anticipated to keep its top position over the forecast period. Most preferred first-line therapy for infrequent and mild symptoms is antacids, as the therapy neutralize the secretion of gastric acid immediately. Convenient OTC (over-the-counter) accessibility various forms such as syrups, powders and tablets is accountable for the extreme adoption. Moreover, the AHFS (American Hospital Formulary services), amongst other countries, enlisted over 120 preparations too advocate.

In 2016, the second largest segment was found to be PPIs as it is the most common medication prescription type for the diseases such as heartburn. Generics inflow leading to the loss of exclusiveness of popular drugs, including Prilosec and Nexium, is estimated to negatively affect the sales of branded versions. A further decrease is appearing more with the expected expiration of other patented drugs, such as Dexilant.

Regional Insights

In 2016, the largest region was found to be North America in terms of share for GERD market. Every year, GERD symptoms are experienced by more than 80 million people in the U.S., of which, approximately 25 million patients suffer from acid reflux and heartburn daily and approximately 60 million patients monthly.

Moreover, outpatient clinic visits for GERD disorder in the U.S. has been increased in the past few years because of the more prone geriatric population to develop acid reflux and heartburn. On the contrary, the Asia Pacific is estimated to witness the fastest growth rate. The increasing geriatric population and dietary and lifestyle risk factors such as diet with high fat and obesity, is anticipated to drive the growth. In developing countries, the inclination towards self-medication is quickly increasing because of the affordability and availability of OTC antacids as in China and India.

Competitive Insights

Competitive market, which is generics-driven is creating a pressure on the prices of drug with decreased retail sales, which will stimulate stationary growth in future. Companies producing them range from high to medium on the basis of competitive rivalry. Eisai Co., Ltd.; AstraZeneca PLC; GlaxoSmithKline PLC; Johnson & Johnson and Takeda Pharmaceutical Co., Ltd.; are some of the top key players. In addition, Daewoong Pharmaceutical Co., Ltd.; SRS Pharmaceuticals Pvt. Ltd.; SFJ Pharmaceuticals Group and Ironwood Pharmaceuticals, Inc. are some emerging companies.

Among others, RaQualia Pharma, Inc. and Ironwood Pharmaceuticals, Inc. are focusing more on development of new generic molecules, which involves novel and existing drug mechanisms as a part of the strategy to enter into the competition. Many generic players are also trying to focus on these spaces in an attempt to capture a larger share by the new version to replace the patent expired drugs.  

Read full research report:

https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market

Download free request sample:

https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market/request-sample

[pricedaniel238]

H2 Receptor Antagonist Market Major Trends, Analysis and Outlook

H2 Receptor Antagonist Market Major Trends, Analysis and Outlook

The H2 Receptor Antagonist market research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to H2 Receptor Antagonist…

[sapanas]

Upper GI series Market Analysis, Share, Size, Trends And Industry Growth

An upper gastrointestinal (UGI) series is radiographic examination of the GI tract for any abnormalities. It is also known as constant radiography. The global upper GI series market by Market Research Future takes a look at the various diseases affecting the GI tract, developments in X-rays, and new projections for the period of 2017 to 2023 (forecast period). The impact of the COVID-19 pandemic and analysis of its effects as well as the opportunities for the technology are also discussed in the report.

Upper GI series market Scope

The global upper GI series market is expected to grow at a CAGR of 4.5% during the forecast period. Huge prevalence of GI disorders is one of the primary drivers of the market. The large healthcare expenditure allocated to detection of GI distress can fuel the market. GI disorders had accounted for close to USD 110 billion in 2005 in the U.S. alone. The interest of the pharmaceutical industry as well as large patient pool can be lucrative for the market in the long run.

Developments in cost-effective treatments, government research for GI disorders, and the large geriatric populace are other drivers of the market. Effective treatments such as acid suppressants, histamine H2 receptor antagonists, and proton pump inhibitors are expected to drive the market to great heights.

But high costs of treatment can impair market growth.

Upper GI series market Segmentation

The global upper GI series market is segmented by test type, imaging material, application, and end users.

On the basis of test type, it is divided into standard barium upper GI series and double-contrast upper GI series.

On the basis of imaging material, the market is segmented into barium swallow, barium follow-through, and barium meal. The barium swallow segment is likely to fetch huge returns for the global upper GI series market owing to its ability to detect abnormalities in esophagus, stomach, and intestines.

On the basis of application, the market is segmented into ulcers, esophageal reflux, esophageal varices, hiatal hernias, and others.

On the basis of end users, it is segmented into hospitals, clinics & laboratories, and others.

Upper GI series market Regional Analysis

Geographically, the global upper GI series market looks at the regions of the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

The Americas accounted for the largest market share for upper GI series. Factors driving market growth are the large patient population, well-developed healthcare, and increasing geriatric population. Reimbursement policies as well as adoption of advanced diagnostic methods can create plenty of opportunities for the upper GI series market. Approval of the use of disposable devices has paved the way for new strides for the industry in the region. Recently, Boston Scientific gained approval for the use of disposable duodenoscopes for diagnosis of bile duct disorders in the U.S.

Europe is the second largest market, followed by Asia Pacific. The region is expected to be lucrative due to revised codes to be outlined for upper GI series by reputed healthcare associations. A well-developed healthcare network and trained personnel in radiography can facilitate the growth of the upper GI series market.

APAC is the fastest growing market for upper GI series due to presence of many developing countries and cost effective treatments. Change in eating habits and alarming cases of hepatitis C can spur the need for constant radiography. Lastly, the MEA region has the least market share.

Upper GI series market Competition

GastroIntestinal Specialists LLC., Alfa Wassermann SPA, Cadila Pharmaceuticals Limited, Purdue Pharma L.P., Novadaq Technologies Inc., AstraZeneca, Eisai Co., Ltd, and Ironwood Pharmaceuticals Inc. are key players of the global upper GI series market.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/upper-gi-series-market-826

[adwaitcoherent]

By 2026, Ranitidine Market To Surpass US$ 485.4 Million - Coherent Market Insights

Ranitidine Market To to exhibit a CAGR of 1.8% over the forecast period (2018 - 2026).

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2131

Description:

Healthcare professionals have been keenly interested in the treatment of gastroesophageal reflux disease (GERD) and stomach & intestinal ulcer owing to its increasing prevalence. GERD is common health problem, which leads to serious medical complications and further huge medical expense in its diagnosis and treatment. The two most frequently observed symptoms associated with GERD are heartburn and acid regurgitation. Usually, over-the-counter antacids, proton pump inhibitor, and H-2 receptor blockers are used to decrease the effects of stomach acids or to block acid production.

 Ranitidine is a histamine H2 antagonists and available as both over-the-counter (OTC) and prescription drug, indicated in the treatment of gastroesophageal reflux disease (GERD). Ranitidine decreases the acid production from stomach for up to 12 hours. Also, ranitidine is commonly used in erosive esophagitis, peptide ulcer disease, and Zollinger–Ellison syndrome. It could be taken orally or intravenously.

 The global ranitidine market size was valued at US$ 412.4 Mn in 2017, and is expected to witness a CAGR of 1.8% over the forecast period (2018 – 2026).

 Global Ranitidine Market Share (%), By Application: 2018 & 2026

Ranitidine  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2018)

 Growing Research and Development (R&D) on Ranitidine is expected to Boost Market Growth  

 Various government and private research organizations are increasingly engaged in research and development studies to increase the efficacy of ranitidine and examine possible potential of ranitidine to increase future scope of ranitidine market.

 Furthermore, various clinical trials are currently undergoing to identify and compare efficacy between ranitidine and other proton pump inhibitors such as esomeprazole and rabeprazole to measure gastric acid reduction in stomach. With the result of these studies, the efficacy of ranitidine is expected to improve and offer better treatment regimes in reducing excessive gastric acid production in the near future.

 For instance, in November 2015, a study to compare the efficacy of rabeprazole extended release (ER) 50 mg versus ranitidine 150 mg in treating erosive gastroesophageal reflux disease (eGERD) is currently in Phase III clinical stage.

  Global Ranitidine Market Share (%), By Form: 2018 & 2026

Ranitidine  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2018)

 Rising Cases of Various Gastric Ulcers and Digestive Diseases is expected to Increase Growth of the market  

 High prevalence of gastroesophageal reflux disease (GERD), intestinal & stomach ulcers, esophagitis, heartburn, and other digestive diseases due to unhealthy lifestyle, changing dietary patterns will lead to increase in demand for ranitidine-based medications in the near future. According to Florida Hospital, 2018 U.S. data statistics, in the U.S. over 60 million adults suffer from acid reflux symptoms every month. Furthermore, the source states that each day an estimated 25 million of the 60 million adults suffers from acid reflux symptoms. Also, according to the same source, about 20% of people with acid reflux will develop gastroesophageal reflux disease (GERD) in the near future.

 Heartburn with or without regurgitation is identified as one of the prime symptoms of gastroesophageal reflux disease (GERD). According to World Gastroenterology Organization (WGO), 2015, prevalence of GERD is rapidly increasing worldwide, with differences reported in prevalence ranging from 2.5% to 6.6% in Eastern Asia while slightly higher up to 13.8% to 25.8% in North America.    

 The reason for high prevalence of GERD is not entirely clear, however, it appears to be correlated with increasing prevalence of obesity, and several dietary factors. In obese patients, excess belly fat exert more pressure on the stomach, which causes backflow of acid causing heartburn. Increasing number of obese patients across the globe will indirectly increase GERD cases and this is expected to fuel growth of ranitidine market. According to World Health Organization (WHO), in 2016, over 1.9 billion adults aged 18 years and above were overweight, of which over 650 million were obese, worldwide. Furthermore, GERD is associated with possible risk of Barrett’s esophagus: a premalignant condition that damages the esophagus tube.  

 However, stringent regulatory guidelines of FDA in the manufacturing of finished drugs will limit growth of ranitidine market. For instance, in March 2018, the Ministry of Food and Drug Safety, South Korea banned the imports of 150 mg Zantac (ranitidine) supplied by GlaxoSmithKline (GSK) Korea, for 4 months (March to June 2018) due to its different shape and coatings. According to the same source, South Korea’s Ministry of Food and Drug Safety report, GSK violated Pharmaceutical Affairs Act by changing the approved shape of Zantac. Zantac is supposed to be white and round with thin film-coatings on both side, while GSK distributed Zantac with thick coated film and also coating around some of the tablets were slightly broken. Changes in color, taste, and packaging might hurt the safety and efficacy of drugs, which directly affects the quality of product.  

 Furthermore, one of the major challenges in determining prevalence of GERD is to identify the patients’ suffering with the condition. Patients suffering with GERD-related symptoms do not consult healthcare professionals until the symptom gets severe. . Direct costs associated with GERD disease include costs of over-the-counter and prescription medications, physician office and hospital visits, surgical costs, and costs of treating other possible complications such as Barrett's esophagus and esophageal adenocarcinoma, which may result from the disease. This is expected to limit the growth of ranitidine market, over the forecasted period.    

 Key players operating in the global ranitidine market include GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Strides Pharma Science Limited (StridesShasun), Tocris Bioscience (R & D Systems), Merck KGaA, and Sun Pharmaceutical Industries Limited among others.

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

 Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2131

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave.  #3200  Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[medicalnewstoday]

Global  H2 Receptor Antagonist  Market research to Hold a High Potential for Growth by 2019-2029

The ~US$ 2.6 billion market for H2 receptor antagonist has been envisaged to witness lethargic growth prospects over the years to come., according to a recent research study of XploreMR. The research report for H2-receptor antagonists market elaborates the dynamics that are related to the growth and fragmented nature of the market. The market is expected to expand at a considerable rate, which can be majorly attributed to the growing incidence of gastroesophageal reflux disease (GERD) as well as the increasing adoption rate of H2-receptor antagonists.

Research shows that the growing adoption of proton-pump inhibitors is a major factor due to which the H2-receptor antagonists market is likely to witness sluggish growth over the forecast period. In terms of influencing factors, presence of generic OTC H2-receptor antagonists and prevalence of GERD and peptic ulcer population are the clear. A present, the disease trend observed around the world indicates that eastern countries are more prone to regurgitation-dominant GERD and western countries observe heartburn-dominant GERD.

Get Sample Copy of this Report @ https://www.xploremr.com/connectus/sample/3989

The H2-receptor antagonists market has not been experiencing considerable growth over the past few years owing to the availability of generic medications, growth in the number of local players, as well as the adverse effects associated with the consumption of H2-receptor antagonists. There are severe health risks associated with the consumption of H2-receptor antagonists, which include headaches, fatigue, abdominal pain, diarrhea, and drowsiness. The use of H2-receptor antagonists for patients with renal difficulties, hepatic impairment, or patients who are aged 50 years, can lead to adverse effects to the central nervous system. Drug interactions with the use of H2-receptor antagonists may go wrong at times, and a therapeutic increase in gastric pH is likely to disrupt the mechanism of drugs that require an acidic environment for dissolution.

Evolving Adoption Patterns, Driven by Strong Alternative Competitors

Consumer preference has changed for H2-receptor antagonists, which limits the market growth for H2-receptor antagonists. The market is already experiencing tough competition from other valuable alternatives, and present effects associated with the consumption of these drugs makes it even worse for manufacturers to label their products. Advisory labels for H2-receptor antagonists is mandatory, however, the present physical differences among consumers can lead to difficulties that they are not aware of.

The demand-side trends, which show increasing access to affordable generic versions of treatment, are indicating low spending for treatment, which is offsetting the increasing spending on branded drugs. The adoption of H2-receptor antagonists has changed over the years with the introduction of Zantac, which is considered to be the first billion-dollar drug to face growing competition from proton-pump inhibitors. There are other occasionally used alternative drug types available for cases, which include potassium-competitive acid blockers, antacids, and cytoprotective agents.

Request for Check Discount @ https://www.xploremr.com/connectus/check-discount/3989

Although the H2-receptor antagonists market is mature and highly competitive, most segments of the H2-receptor antagonists market are either saturated or nearing saturation. Extensive pricing competition among generic manufacturers facilitate a continuous demand growth, which is in relation to the adoption of H2-receptor antagonists. Most of the major players in the pharmaceutical industry are manufacturing proton-pump inhibitors.

The adoption and clinical benefits associated with proton-pump inhibitors are larger in number, hence, a smaller number of manufacturers are present in the H2-receptor antagonists market. Clinically better products with affordable pricing can still act as significant influencers for this H2-receptor antagonists market. In the face of global volatility, manufacturers gain profits due to the reliability, productivity, and awareness offered by loyal consumers.

Targeting countries for marketing H2-receptor antagonists is most important as the emergence and presence of generic manufacturers has led to a more competitive market structure. Moreover, entering a H2-receptor antagonists market with many local players providing drugs at a considerably low cost is a challenge for most of the global manufacturers.

Request Methodology of this Report @  https://www.xploremr.com/connectus/request-methodology/3989

At present, the global H2-receptor antagonists market is highly fragmented, with the presence of few global manufacturers and a large number of regional manufacturers. Some of the key H2-receptor antagonist manufacturers include Alembic Pharmaceuticals Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Sanofi S.A., Abbott, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Cadila Healthcare Ltd, and GlaxoSmithKline Plc.

About us: XploreMR is one of the world’s leading resellers of high-quality market research reports. We feature in-depth reports from some of the world’s most reputed market research companies and international organizations. We serve across a broad spectrum – from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information. Our team comprises an eclectic mix of experienced market research specialists, search engine specialists, web designers, online marketers, and business writers. The team is highly committed to going above and beyond, and serving the research needs of our clientele. Contact us:

111 North Market Street, Suite 300, San Jose, CA 95113, United States Tel: +1-669-284-0108 E-mail: sales@xploremr.com Website: www.xploremr.com

[ihealthcareanalyst]

Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast 2018-2023

Scleroderma is an autoimmune disease affecting the skin and other organs of the body. There are two main types of the disease: the localized form (called localized scleroderma, limited scleroderma, or morphea) and the systemic form (called systemic scleroderma, diffuse scleroderma, generalized scleroderma, or systemic sclerosis). Laboratory testing can identify antitopoisomerase or anticentromere antibodies. X-rays and computerized tomography (CT) scans are used to look at bone abnormalities. Thermography can detect differences in skin temperature between the lesion and normal tissue. Ultrasound and magnetic resonance imaging (MRI) can aid soft tissue assessment. There are no treatments for scleroderma itself, but organ system–specific complications are treated and relief of symptoms is often achieved with vasodilators such as calcium channel blockers, alpha blockers, serotonin receptor antagonists, angiotensin II receptor inhibitors, statins, local nitrates or iloprost. Effective treatments are available for those with severe disease, including acute kidney disease, pulmonary hypertension, lung inflammation and gastrointestinal problems. Browse Scleroderma Diagnostics and Therapeutics Market by Indication (Localized, Systemic), Test Type (Blood Tests, Electrocardiogram and Echocardiogram, Imaging Techniques, Pulmonary Function Tests, Skin Biopsy), Drug Class (Calcium Channel Blockers, Chelating Agents, Corticosteroids, Endothelin Receptor Agonists, Immunosuppressive Agents, PDE-5 Inhibitors, Prostacyclin Analogues, ACE Inhibitors, H2 Blockers, Proton Pump Inhibitors) and Forecast 2018-2023 at https://www.ihealthcareanalyst.com/report/scleroderma-diagnostics-therapeutics-market/ The global scleroderma diagnostics and therapeutics market segmentation is based on indication (localized, systemic), test type (blood tests, electrocardiogram and echocardiogram, imaging techniques, pulmonary function tests, skin biopsy), drug class (calcium channel blockers, chelating agents, corticosteroids, endothelin receptor agonists, immunosuppressive agents, PDE-5 inhibitors, prostacyclin analogues, ACE inhibitors, H2 blockers, proton pump inhibitors). The global scleroderma diagnostics and therapeutics market report provides market size (Revenue US$ Million 2018-2023), market share, trends and forecasts growth trends (CAGR%, 2018-2023). The global scleroderma diagnostics and therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global scleroderma diagnostics and therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. Major players operating in the global scleroderma diagnostics and therapeutics market and profiled in this report include Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Corbus Pharmaceutical Holdings Inc., Cytori Therapeutics, Inc., Cumberland Pharmaceuticals, Inc., F. Hoffmann La Roche Ltd., Gilead Sciences, Inc., Merck KGaA, Pfizer, Inc., and Sanofi. 1. Indication 1.1. Localized 1.2. Systemic 2. Test Type 2.1. Blood Tests 2.2. Electrocardiogram and Echocardiogram 2.3. Imaging Techniques 2.4. Pulmonary Function Tests 2.5. Skin Biopsy 3. Drug Class 3.1. Calcium Channel Blockers 3.2. Chelating Agents 3.3. Corticosteroids 3.4. Endothelin Receptor Agonists 3.5. Immunosuppressive Agents 3.6. PDE-5 Inhibitors 3.7. Prostacyclin Analogues 3.8. Others (ACE Inhibitors, H2 Blockers, Proton Pump Inhibitors, etc.) 4. Geography (Region, Country) 4.1. North America (U.S., Canada) 4.2. Latin America (Brazil, Mexico, Rest of LA) 4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 4.4. Asia Pacific (Japan, China, India, Rest of APAC) 4.5. Rest of the World 5. Company Profiles 5.1. Actelion Pharmaceuticals, Inc. 5.2. Bayer AG 5.3. Boehringer Ingelheim 5.4. Corbus Pharmaceutical Holdings, Inc. 5.5. Cumberland Pharmaceuticals Inc. 5.6. Cytori Therapeutics, Inc. 5.7. F. Hoffmann La Roche Ltd. 5.8. Gilead Sciences, Inc. 5.9. Merck KGaA 5.10. Pfizer, Inc. 5.11. Sanofi To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/scleroderma-diagnostics-therapeutics-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com

[forlawfirmsonlymarketing]

Zantac Use May Increase the Risk of Breast Cancer

Women using Zantac could have a higher chance of developing a type of breast cancer compared to those not using the medication, according to a peer-reviewed study. If your firm represents plaintiffs injured by drugs, female Zantac users who later develop ductal carcinoma are potential clients worth pursuing. Study looks at Zantac’s active ingredients and their impact on hormone A peer-reviewed study by the American Association for Cancer Research and the American Society of Preventive Oncology published in 2008 examined the relationship between H2 antihistamine-blockers like Zantac and breast cancer. Histamine H2-receptor antagonists, also known as H2 blockers, have been used to treat duodenal and gastric ulcers and prevent their return, reports the Mayo Clinic, by limiting the amount of acid produced in the stomach. Over the counter versions were to relieve or prevent heartburn, acid indigestion, and sour stomach. The Food and Drug Administration asked the manufacturers of Zantac and those making similar medications to stop selling the products in April. Using them can cause Nitrosodimethylamine (NDMA) to be released in the body. That organic compound has been linked to an increased risk of esophageal, oral cavity, and pharynx cancers. Ranitidine can boost hormone levels and increase the risk of cancer The study didn’t find a causal link between ranitidine (Zantac’s active ingredient) and breast cancer in general but it did suggest that those regularly using these medications had an increased risk of ductal carcinoma. It found, “current use of ranitidine may increase risk of hormone receptor-positive ductal carcinoma…” Some H2 blockers, especially cimetidine and ranitidine, increase levels of the hormone prolactin. Its role in promoting breast cancer growth isn’t as well-known as estrogen and progesterone, but prolactin’s effect on breast cancer has drawn increasing attention, according to one 2017 study. Both animal and laboratory data suggest prolactin is involved in the creation of tumors by promoting cell creation, increasing the number of cells changing from one type to another, improving a tumor’s ability to attract blood flow and invade healthy tissue. This relationship between increased prolactin levels and postmenopausal breast cancer risk makes the use of H2 blockers a potential risk factor. The 2008 study authors combined data from two population-based case-control studies conducted in western Washington. They looked at the possible connection between using H(2) blockers and the risk of developing different types of breast cancers among 1,941 cases and 1,476 control group members 55 to 79 years old. A study found chances of a type of ductal carcinoma increase with the use of ranitidine The study found women in this age range using H(2) blockers with ranitidine were 2.4 times more likely to develop estrogen receptor-positive/progesterone receptor-positive ductal carcinoma, compared to others who didn’t use the medication. The study concluded that H(2) blocker use doesn’t increase the risk of breast cancer in general, but it may increase the risk of hormone-receptor-positive ductal carcinoma. It recommended that further studies should be done to confirm their findings. ForLawFirmsOnly Marketing can help your law firm grow How do you compete against other firms for quality, profitable Zantac cases? Hire ForLawFirmsOnly Marketing. Avoid the problems and expensive marketing and advertising. Reach out to potential clients ready, willing, and able to retain your legal services. We can obtain the highest quality leads so you won’t have to put in the work to do it yourself. We use highly sophisticated, targeted marketing and advertising campaigns to get the results you can’t get on your own. Get started before your competitors do. There is a limit to how many clients we can onboard. Contact us for a quote. Call 855-943-8736 or use our Request A Quote form. Edward Lott, Ph.D., M.B.A. President and Managing Partner ForLawFirmsOnly Marketing, Inc. Ed can be reached at (or visit his website) edl@forlawfirmsonly.com 855-943-8736 ext. 101 www.ForLawFirmsOnly.com

https://www.forlawfirmsonly.com/zantac-use-may-increase-the-risk-of-breast-cancer/